EMA grants orphan drug designation to AlloVir’s Viralym-M
Viralym-M is the company’s lead allogeneic, off-the-shelf, multi-virus specific T-cell therapy, being developed for the treatment and prevention of serious viral diseases caused by six commonly occurring, devastating